Revelation Biosciences, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. The company is a clinical-stage biopharmaceutical developer with no approved products and no product revenue. Share and per-share information is affected by reverse stock splits; verify the applicable basis when comparing figures.
Key financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.15 million | $5.38 million |
| General and administrative expense | $4.51 million | $5.49 million |
| Total operating expenses / operating loss | $8.66 million | $10.86 million |
| Other income, net | $8.54 million | $0.03 million |
| Net loss | $0.12 million | $10.83 million |
| Net cash used in operating activities | $7.29 million | $11.22 million |
| Cash and cash equivalents at year-end | $11.99 million | $5.25 million |
- The sharp reduction in reported net loss was chiefly due to an $8.33 million noncash gain from revaluing warrant liabilities—not operating profitability. Operating loss remained $8.66 million. Product margins are not meaningful because the company has no product sales.
- FY2023 financing activities provided $14.03 million, primarily from the February 2023 public offering; cash increased by $6.74 million during the year.
- At December 31, 2023, total assets were $12.21 million, total liabilities $5.56 million, and stockholders’ equity $6.65 million. Current liabilities included $2.91 million in deferred underwriting commissions and a $0.14 million warrant liability. The filing reports no material non-cancelable operating commitments and no off-balance-sheet arrangements.
- Management and the auditor state that substantial doubt exists about the company’s ability to continue as a going concern. Including approximately $5.4 million net proceeds from a February 2024 offering, management said available cash was not expected to fund operations for one year after the financial statements were issued. Additional financing is needed.
Material changes and business developments
- R&D expense fell $1.23 million year over year, primarily as spending on discontinued REVTx-99a and REVTx-99b clinical studies ended. This was partly offset by higher manufacturing and other program costs, including preclinical and clinical-preparation work for GEM-SSI and GEM-AKI.
- G&A expense declined $0.98 million, mainly because of lower other expenses, including directors’ and officers’ insurance.
- The portfolio is focused on Gemini-based candidates: GEM-SSI for surgical-site infection, GEM-AKI for acute kidney injury, and GEM-CKD for chronic kidney disease. The filing describes supportive preclinical findings; it does not establish clinical efficacy for these candidates.
- On January 25, 2024, the company effected a 1-for-30 reverse stock split. In February 2024, it raised approximately $6.2 million gross and $5.4 million net through a public offering of shares and warrants. The offering also reset the exercise price of outstanding Class C warrants to $4.53. These post-year-end events do not change FY2023 results but affect liquidity and potential dilution.
- The company regained Nasdaq minimum-bid-price compliance in February 2024. It had previously received notices concerning bid-price and stockholders’ equity listing requirements.
Outlook, risks, contingencies, and unusual items
- Management expected Phase 1 safety and biomarker-activity data for GEM-SSI and GEM-AKI in summer 2024. It planned a subsequent Phase 1b study of GEM-SSI in colorectal surgery patients and GEM-AKI in cardiac-surgery patients; the timing and completion of these plans depend on funding and regulatory progress. Additional nonclinical CKD work was planned for 2024.
- The company expects continued operating losses and negative operating cash flows, and does not expect product-sale revenue for at least several years, if ever. It has no committed external funding source; financing may be unavailable, dilutive, or on unfavorable terms, potentially forcing development delays or reductions.
- Development and supply risks include early-stage candidates, uncertain clinical and regulatory outcomes, reliance on third-party manufacturers, and a single PHAD supplier, Avanti Polar Lipids, without a long-term supply agreement. The company says it has purchased enough material for planned clinical studies.
- LifeSci Capital seeks approximately $5.3 million plus interest in a pending dispute over banking and advisory fees. A magistrate judge recommended summary judgment for LifeSci in December 2023; the company objected, and the trial judge’s review remained pending. The company recorded $2.91 million of deferred underwriting commissions as a liability and did not record additional disputed amounts because they could not be determined.
- A-IR Clinical Research seeks £1.6 million plus interest and costs over disputed invoices. The company contests the claim and recorded no liability because the amount, if any, could not be determined.
- FY2023 results include substantial noncash warrant remeasurement effects. The Class C warrant liability was valued using a Level 3 Monte Carlo model; changes in estimated fair value can materially affect reported earnings.
- The company reported effective disclosure controls and internal control over financial reporting as of December 31, 2023. Its audit opinion was unqualified, but included a going-concern uncertainty paragraph.
Important facts for investors to verify
- Current cash runway after the February 2024 financing, expected operating spend, and the amount and timing of additional capital required.
- Whether planned Phase 1/Phase 1b studies have the necessary regulatory clearances, funding, materials, and enrollment, and whether the stated summer 2024 data expectations were achieved.
- Final status and potential financial exposure of the LifeSci and A-IR disputes, including any amounts not accrued in the statements.
- Warrant terms, valuation assumptions, exercise activity, and resulting potential dilution, including the Class C repricing and February 2024 Class D issuance.
- Share counts and per-share comparisons after the 1-for-35 split in 2023 and 1-for-30 split in 2024; confirm the relevant figures are on a consistent basis.
- Supply continuity and manufacturing capacity for PHAD and clinical product, plus compliance with milestones under the Vanderbilt license.